Glycogen synthase kinase-3␤ (GSK3␤) is a central figure in many intracellular signaling systems and is directly regulated by lithium. Substantial evidence now indicates that an important property of the mood stabilizer, lithium, is to influence GSK3␤-linked signaling pathways. This raises the possibility that other mood stabilizers act in a similar manner, which may include modulation of signaling systems leading to GSK3␤, direct regulation of GSK3␤ or regulation of signaling intermediates downstream of GSK3␤. Downstream targets of GSK3␤, and thus potential targets of mood stabilizers, are several key transcription factors, including ␤-catenin, AP-1, cyclic AMP-response element binding protein, NFB, Myc, heat shock factor-1, nuclear factor of activated T-cells and CCAAT/enhancer-binding proteins. GSK3␤ also is an important modulator of cell death, which may be a consequence of its regulatory effects on transcription factor activities. GSK3␤ facilitates apoptosis, and lithium's inhibition of GSK3␤ supports cell survival. Thus, signaling systems determining cell fate appear to be important targets of mood stabilizers, and these may include signaling pathways encompassing GSK3␤, including transcription factors regulated by GSK3␤. Molecular Psychiatry (2002) 7, S35-S45.
Introduction
During the past 5 years, new vistas have opened for defining the actions of mood-stabilizing drugs because of a tremendously increased understanding of intracellular signaling pathways and several breakthrough findings. These new concepts include the following: (1) glycogen synthase kinase-3␤ (GSK3␤) is now recognized as a central figure in many signaling systems (and especially notable is its regulatory influence on the activation state of several critical transcription factors); (2) the activity of GSK3␤ has a major influence on cell survival, with hyperactive GSK3␤ increasing the susceptibility of cells to the lethal consequences of a wide variety of insults; and (3) lithium is both a direct inhibitor of GSK3␤ and a broadly acting neuroprotectant, facilitating cell survival from a wide range of insults. We propose that these two actions of lithium are directly linked, and that inhibition of GSK3␤ accounts for much of lithium's neuroprotective capacity. Furthermore, based on these recent developments, it appears likely that signaling systems linked to GSK3␤ constitute a critical target for mood-stabilizing drugs. Recent findings concerning these topics are reviewed below, followed by an overview of how Correspondence: RS Jope, Department of Psychiatry and Behavioral Neurobiology, Sparks Center, Room 1057, University of Alabama at Birmingham, Birmingham, AL 35294-0017, USA. E-mail: jopeȰuab.edu actions on signaling systems associated with GSK3␤ may be a key target for mood-stabilizing drugs.
Signaling systems associated with GSK3␤
GSK3␤ entered the lexicon of mood-stabilizer researchers in 1996 when it was found that lithium potently and selectively inhibits GSK3␤.
1,2 GSK3␤, originally identified as a kinase that phosphorylates glycogen synthase, 3 is rapidly becoming recognized as a central regulator of intracellular signaling cascades because of the wide array of substrates that it phosphorylates. These include cytoskeletal proteins, metabolic and cell cycle proteins, and a remarkable number of key transcription factors. The relationship between GSK3␤ and transcription factors appears to be particularly important from the standpoint of actions of mood-stabilizer drugs. This is because regulation of transcription factors influences cell function by regulating gene expression, which for a long time has been thought to be an important component of the therapeutic actions of mood stabilizers. 4 Additionally, with the recent revelations of the neuroprotective capacity of lithium, as discussed further in later sections of this article, it is notable that the regulation of GSK3␤ directly impacts cell survival. Thus, it is now imperative to identify how mood stabilizers affect GSK3␤, signaling systems that regulate GSK3␤, and signaling systems that are regulated by GSK3␤, especially transcription factors.
GSK3␤ is constitutively active, but its activity can be modulated by phosphorylation and by protein complex formation. Phosphorylation of GSK3␤ on Ser-9 inhibits its activity. 5 One prominent pathway mediating this modification involves the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway. Stimulation of PI3K leads to the phosphorylation and activation of Akt by phosphoinositide-dependent kinases. Activated Akt phosphorylates Ser-9 of GSK3␤, which inhibits its activity. 6 Several other kinases are capable of phosphorylating Ser-9 of GSK3␤, including p70 S6 kinase, p90Rsk, protein kinase C and protein kinase A. [7] [8] [9] Thus, a diverse group of signaling systems exert inhibitory control on GSK3␤ (Figure 1) . In contrast to ser-9 phosphorylation, phosphorylation of GSK3␤ on Tyr-216 increases its activity. 10 The mechanisms regulating Tyr-216 phosphorylation are not entirely clear; this modification has been attributed to autophosphorylation 11 and it is also increased by treatments that elevate intracellular calcium, activate Fyn or induce apoptosis. [11] [12] [13] [14] In addition to phosphorylation, GSK3␤ activity can be modulated by protein complex formation. This has been examined in the greatest depth with regard to the evolutionarily conserved Wnt/wingless signaling pathway. 15 GSK3␤, along with the product of the adenomatous polyposis coli gene, and the scaffolding protein Axin, functions as a negative regulator of the Wnt signaling pathway. When the Wnt signaling pathway is inactive (ie, Wnt ligand is not bound to the Frizzled receptor), the GSK3␤/adenomatous polyposis coli gene product/Axin protein complex facilitates the phosphorylation of ␤-catenin by GSK3␤, which results in targeting ␤-catenin for degradation. 16, 17 Activation of Figure 1 Signaling pathways regulating GSK3␤ and transcription factors regulated by GSK3␤. The scheme depicts five kinases that are known to phosphorylate GSK3␤ on serine-9, which inhibits the activity of GSK3␤. When active, GSK3␤ phosphorylates eight transcription factors, modulating their activities in the direction indicated by the arrows associated with each transcription factor.
the Wnt signaling pathway inhibits GSK3␤ activity. In this case, the binding of Wnt to Frizzled activates the protein Disheveled which, in combination with GSK3␤-binding proteins (GBP, Frat-1 and -2), binds and contributes to the inactivation of GSK3␤. 18, 19 GSK3␤ inactivation results in ␤-catenin accumulation and translocation to the nucleus where it binds TCF/LEF proteins, which facilitate the transcription of Wnt target genes. These studies demonstrate both the regulatory effects of protein complex formation in controlling the actions of GSK3␤, and the critical role that GSK3␤ plays in regulating the ␤-catenin/TCF/LEF transcription factors.
In addition to ␤-catenin, GSK3␤ modulates the activities of several other key transcription factors ( Figure 1 ). The first of these that was found to be regulated by GSK3␤ is AP-1. AP-1 is composed of homoand hetero-dimer protein complexes primarily consisting of proteins in the Jun and Fos families. AP-1 is activated by a wide range of stimuli, such as protein kinase C, neurotransmitters, growth factors and stressors such as heat shock and oxidative stress. The activation of AP-1 is regulated by phosphorylation of constituent proteins. For example, phosphorylation of Ser-63 and Ser-73 of cJun contributes to its activation. 20, 21 GSK3␤, on the other hand, phosphorylates cJun on Thr-239, Ser-243 and Ser-249, modifications that decrease its activity. Initially Boyle et al 22 reported that recombinant Jun proteins phosphorylated in vitro by GSK3␤ had decreased activity, and that mutation of Ser-243 to phenylalanine both blocked phosphorylation of Thr-239 and Ser-249 by GSK3␤, and enhanced the transcriptional activity of cJun. In subsequent stud-ies, transcriptional activation of AP-1 was reported to be inhibited by the Drosophila kinase Shaggy, a kinase that shares homology with GSK3␤, 23 and transient overexpression of GSK3␤ in mammalian cells inhibited AP-1 activation. 24 Together, these findings illustrate the significant inhibitory effect that GSK3␤ has on the activity of AP-1, a transcription factor that influences numerous important cellular functions.
Cyclic AMP-response element binding protein (CREB), a nuclear phosphoprotein, controls the expression of genes containing promoters with the cyclic AMP response element, CREB is particularly important in neuronal processes, as it plays a critical role in long-term memory, synaptic plasticity and cell survival. 25, 26 Phosphorylation of CREB on Ser-133, which is catalyzed by several kinases, is necessary for CREB to be transcriptionally active. Phosphorylation of CREB at Ser-133 creates a consensus site for phosphorylation on Ser-129 by GSK3␤, 27 an example of hierarchical phosphorylation that is a common characteristic of many GSK3␤ substrates. Although it is widely accepted that GSK3␤ phosphorylates CREB, there are conflicting reports about the functional effect of this modification of CREB. Initially, Fiol et al 28 provided evidence that GSK3␤ facilitated the activation of CREB. In this study, cyclic AMP-induced CREB activation was potentiated in F9 cells overexpressing GSK3␤, and CREB activation was impaired in PC12 cells transfected with CREB containing a mutation in the GSK3␤ phosphorylation site. 28 In contrast, Bullock and Habener 29 reported that GSK3␤-mediated phosphorylation of CREB attenuated protein kinase Ainduced CREB DNA binding activity. Further evidence that GSK3␤ negatively regulates CREB comes from the finding that protein kinase A directly phosphorylates GSK3␤ on Ser-9, inhibiting GSK3␤ activity, 9 indicating that activation of protein kinase A both stimulates CREB activation and inhibits GSK3␤ activity. Further evidence that GSK3␤ inhibits the activation of CREB was found in human neuroblastoma SH-SY5Y cells, in which inhibition of GSK3␤ facilitated CREB activation, whereas increased GSK3␤ activity blocked CREB activity. 30 Thus, as with ␤-catenin and AP-1, GSK3␤ is an inhibitory modulator of CREB activity.
Cells are constantly exposed to stressful conditions that must be counteracted by cellular signaling mechanisms. One of the most important cellular mechanisms used to defend against potentially lethal insults is the heat shock response, a response that is mediated by the transcription factor, heat shock factor-1 (HSF-1). Besides elevated temperatures, HSF-1 can be activated by many other stressors, such as oxidative stress, osmotic stress, and agents such as heavy metals. 31 Activation of HSF-1 results in the expression of heat shock proteins which chaperone misfolded proteins that otherwise could accumulate to toxic levels in stressed cells. The signaling mechanisms that activate HSF-1 have not been completely elucidated, but there is substantial evidence that GSK3␤ has an inhibitory effect on the activation of HSF-1.
32-36 HSF-1 activity is regulated in part by phosphorylation of its regulatory Molecular Psychiatry domain, located between amino acids 221 and 310. 37 Ser-303 of HSF-1 is phosphorylated by GSK3␤ subsequent to phosphorylation of Ser-307 by extracellular signal-regulated protein kinases 1 and 2 (ERK1/2), modifications that inactivate HSF-1. 32, 33, 36, 38 Thus, overexpression of GSK3␤ facilitates HSF-1 inactivation. [34] [35] [36] These results indicate that GSK3␤ is an inhibitor of HSF-1 activity, an action that could limit the ability of cells to adequately activate survival mechanisms in response to cell stresses.
Nuclear factor of activated T-cells (NFAT) was initially described as a transcription factor that mediates the activation of early genes in the immune response, 39 but more recently has been shown to have a variety of functions in non-lymphoid tissues. 40, 41 The NFAT family of transcription factors, which includes NFATc, NFATp, and NFAT4, contain a DNA binding domain that is homologous to the Rel family of proteins. A key limiting factor that affects NFAT function is its nuclear localization. In resting cells, inactive NFAT is phosphorylated and resides in the cytoplasm, but agents that cause an increase in intracellular calcium induce the activation of calcineurin, a calciumstimulated serine/threonine phosphatase. Calcineurin dephosphorylates critical serine residues at the N-terminal domain of NFAT, which facilitates NFAT entry into the nucleus where it binds DNA. 42, 43 When calcineurin is inactivated, NFAT is phosphorylated and exported from the nucleus. It was recently revealed that GSK3␤ is the kinase responsible for phosphorylation of NFAT, thus stimulating its inactivation via export from the nucleus. Beals et al 44 found that GSK3␤ could stoichiometrically phosphorylate NFATc in brain extracts, but only after NFATc was phosphorylated by a priming kinase, and that overexpression of GSK3␤ in COS cells blocked the calcineurin-induced accumulation of NFATc in the nucleus. Subsequently, Graef et al 41 reported that overexpression of GSK3␤, but not other kinases, in hippocampal neurons inhibited NFAT-dependent transcriptional activation, and that overexpression of a dominant-negative GSK3␤ increased NFATc activation. While it is still uncertain if GSK3␤ regulates the activities of other NFAT isoforms, these studies provide strong evidence that GSK3␤ is a critical inhibitory regulator of NFATc.
The transcription factor Myc was originally identified as an oncogene, v-myc, that was transduced by oncogenic avian retroviruses. 45, 46 Myc is a short-lived, nuclear phosphoprotein product of the myc gene family, which includes c-myc, N-myc, L-myc, s-myc, and the non-functional B-myc. Myc regulates cellular growth and differentiation, and Myc proteins are ubiquitously expressed during embryonic development. 47 Unregulated Myc activity blocks the exit of cells from the cell cycle, thus accelerating cell division. 48 Myc consists of a basic helix-loop-helix domain and a leucine zipper motif which are located within the C-terminal region and facilitate dimerization and DNA binding. Myc also contains an N-terminal transactivation domain, which is a proline-rich region highly conserved among the Myc proteins, and is responsible for regulation of Myc transcriptional activation. Myc binds to DNA consensus sequences known as E-boxes, in concert with the stable and constitutively expressed phosphoprotein Max. 49 Max forms heterodimeric complexes with all Myc proteins, and Myc must bind Max to activate transcription of genes containing an E-box. 50, 51 Besides complex formation with Max, phosphorylation also regulates Myc transcriptional activity. Mutagenesis analysis demonstrated that Myc is regulated by phosphorylation of serine and threonine residues located within its N-terminal transcriptional activation domain. 52, 53 Kinases that are believed to phosphorylate Myc in this domain include c-Jun N-terminal kinase, ERKs, cell cycledependent protein kinase-2 and GSK3␤. [52] [53] [54] [55] [56] In vitro studies revealed that GSK3␤ can phosphorylate Myc at Ser-38, Ser-42, Ser-62, and Thr-58, within its transactivation domain, sites considered important for regulation of Myc transcriptional activity in vivo. [53] [54] [55] Phosphorylation of Thr-58 and Ser-62 by GSK3␤ was reported in two studies to negatively regulate Myc activity, resulting in decreased cellular growth and transformation. 53, 55 Thus, it is evident that Myc is likely an in vivo substrate for phosphorylationmediated inhibition by GSK3␤.
CCAAT/enhancer-binding proteins (C/EBP) are a family of transcription factors composed of at least six isoforms, ␣, ␤, ␥, ␦, ⑀ and , that share structural and functional homologies. C/EBP family members contain an activation domain, a DNA-binding basic region, and a leucine zipper that facilitates dimerization of C/EBP family members, as well as that of members of the NFB and Fos/Jun families. 57 C/EBP plays a critical role in cellular differentiation, and is present in a variety of tissues, but is most well known for regulation of genes involved in nutrient metabolism in the liver and differentiation of adipocytes. C/EBP has also been detected in adult brain, specifically in the hippocampus and cortex. 58, 59 For example, Yukawa et al 59 reported that in rat hippocampal neurons, stimulation of signals that potentiate long-term memory formation, such as cyclic AMP or calcium, and overexpression of calcium-calmodulin-dependent kinase IV, stimulated an increase in both C/EBP-␤ and -␦ expression and DNA binding activities. Additionally, insulin causes a rapid dephosphorylation of C/EBP␣, with subsequent decreased C/EBP␣ DNA binding activity. 60 , 61 Ross et al 62 identified GSK3␤ as a primary kinase involved in insulin's regulation of C/EBP activity by demonstrating that insulin-induced activation of PI3K and protein phosphatase 1 inactivated GSK3␤, which resulted in dephosphorylation of two GSK3␤ phosphorylation sites on C/EBP, Thr-222 and Thr-226. These results demonstrate that C/EBP is phosphorylated and activated by GSK3␤, in contrast to the inhibitory influence of GSK3␤ on several other transcription factors.
The NFB family of transcription factors regulates the transcription of numerous cell-survival-associated genes. NFB family members include NFB1 (p50), NFB2 (p52), Rel A (p65), Rel B and c-rel, which bind DNA as homodimers or heterodimers. 63 Normally, NFB is retained inactive in the cytoplasm by the inhibitory protein IB, which binds NFB and prevents its translocation into the nucleus. Upon stimulation, IB becomes phosphorylated and targeted for ubiquitin-dependent degradation, thus freeing NFB for entry into the nucleus to bind DNA. Although NFB is evidently a substrate for phosphorylation by GSK-3␤, the functional effect of this interaction remains inconclusive. Hoeflich et al 64 found that GSK3␤ null mice demonstrated increased sensitivity to tumor necrosis factor-␣ (TNF-␣)-induced toxicity, and that TNF-␣-induced NFB DNA binding activity, which promotes cell survival, was attenuated in GSK3␤ null mouse embryonic fibroblasts compared with wild-type cells. On the other hand, Bournat et al 65 demonstrated an inhibitory influence of GSK3␤ on NFB. Studying Wnt-1-induced NFB activity in PC12 cells, Bournat et al 65 demonstrated that Wnt-1 expression increased PC12 cell survival in an NFB-dependent manner. Furthermore, expression of a dominant negative GSK3␤ mimicked Wnt-1 signaling, which resulted in increased NFB activity and cell survival. The differences in these two studies may indicate a dependence of GSK3␤'s modulatory effect on cell type and on the signaling systems that lead to the activation of NFB, and also underscore the need for further studies to clarify the regulatory role of GSK3␤ on NFB activity.
It is evident that the number of transcription factors known to be regulated by GSK3␤ activity is rapidly growing. These recent results reveal the central importance of GSK3␤ on cell function. Interestingly, in most cases, GSK3␤ is inhibitory towards transcription factor activation, and many of the transcription factors inhibited by GSK3␤ are key components of cell survival mechanisms. It is therefore becoming apparent that modulation of transcription factor activity is one likely mechanisms by which GSK3␤ affects cell fate.
GSK3␤ facilitates apoptosis
In the last few years, GSK3␤ has become recognized as an important modulator of apoptosis. Among the intriguing links between GSK3␤ and cell survival that have been identified are the recent findings that activation of GSK3␤ down-regulates the activities of several transcription factors that are necessary for cell survival, as discussed in the previous section of this article. Furthermore, inhibition of GSK3␤ by activation of the PI3K/Akt signaling pathway, as well as by lithium, a selective inhibitor of GSK3␤, can protect neurons from a wide variety of potentially lethal insults. These observations imply that hyperactive GSK3␤ may be an early contributory factor in cell death. Several reports have directly assessed the role of GSK3␤ in cell fate decisions.
Among the signaling proteins that are known to influence cell fate, GSK3␤ is a relative newcomer. Therefore, only a few studies have appeared investigating its involvement in apoptosis. The earliest evidence that activation of GSK3␤ could be associated with neuronal apoptosis was reported by Takashima et al 66 In this study, treatment of rat hippocampal neurons with the Alzheimer's disease-associated ␤-amyloid protein increased GSK3␤ activity and induced apoptosis, and treatment with GSK3␤ antisense oligonucleotides prevented apoptosis. 66 These findings clearly indicated that GSK3␤ contributes to apoptosis, but, perhaps because of the specialized nature of the apoptotic signal studied (␤-amyloid protein), nearly 5 years transpired before further evidence was reported that GSK3␤ promotes cell death. In a remarkably informative study, Pap and Cooper 67 found that overexpression of active GSK3␤ in PC12 and Rat-1 cells was sufficient to induce apoptosis, and overexpression of catalytically inactive GSK3␤ reduced apoptosis induced by an inhibitor of PI3K. Furthermore, expression of a dominant-negative mutant of p53, or of the survivalpromoting proteins Bcl-2 and Bcl-x L , protected cells from GSK3␤-induced apoptosis. 67 Similarly, an inhibitor of caspase-3 also protected against GSK3␤-induced apoptosis, thus associating activation of the caspase cascade with GSK3␤-mediated apoptosis. 67 These important findings established GSK3␤ as one of the key targets of the anti-apoptotic PI3K/Akt signaling pathway that causes inhibition of GSK3␤, and validated GSK3␤ as a proapoptotic enzyme.
Extending the work of Pap and Cooper, Bijur et al 68 reported that stable overexpression of relatively low levels of GSK3␤ in human neuroblastoma SH-SY5Y cells alone did not alter basal indices of apoptosis. However, this sub-lethal GSK3␤ overexpression greatly facilitated caspase-3 activity and other indicators of apoptosis induced by the widely used apoptosisinducing paradigms of staurosporine or heat shock treatments. Additionally, Bijur et al 68 demonstrated that the apoptosis-enhancing property of hyperactive GSK3␤ could be controlled by treatment with lithium. These results provided direct evidence of a site of action, GSK3␤, contributing to the neuroprotective capacity of lithium, discussed in greater detail in the following section. Withdrawal of trophic factors from cultured neurons is another widely used paradigm of apoptosis. Employing this model, Hetman et al 69 reported that serum deprivation alone, or in combination with exposure to NMDA receptor antagonists or PI3K inhibitors, stimulated GSK3␤ activity prior to the induction of apoptosis, that overexpression of GSK3␤ induced apoptosis and that inhibition of GSK3␤ activity by expression of GSK3␤ binding protein protected cells from trophic factor withdrawal-induced apoptosis. Although Hetman et al 69 provided substantial evidence that GSK3␤ inhibition can confer protection against trophic factor withdrawal-induced apoptosis, Crowder and Freeman 70 reported that apoptosis induced by nerve growth factor withdrawal was independent of GSK3␤, although GSK3␤ was necessary for neuronal death caused by inhibition of PI3K. The potential relevance of GSK3␤-associated cell death to neurodegenerative disease pathologies was reported in two separate studies. Firstly, infection by human immunodeficiency virus-1 (HIV-1) can induce dementia and neuron loss due to neurotoxic factors Molecular Psychiatry such as the HIV-1-associated protein Tat. Maggirwar et al 71 discovered that treatment of rat cerebellar granule neurons with recombinant Tat protein caused an increase in GSK3␤ activity, and a subsequent induction of apoptosis, both of which were amenable to lithium treatment, as lithium-induced inhibition of GSK3␤ activity corresponded with a reduction in Tat-induced apoptosis. Subsequently, Bhat et al 14 found that several apoptotic stimuli induced an increase in GSK3␤ Tyr-216 phosphorylation, and an associated elevation in GSK3␤ activity. However, more pathologically relevant was the finding of increased GSK3␤ Tyr-216 phosphorylation in degenerating neurons in rat cortices following focal cerebral ischemia.
Although few in number, taken together, these reports have established that GSK3␤ is a key pro-apoptotic signaling enzyme in several conditions. The mechanisms by which GSK3␤ facilitates apoptosis are not yet established, but there are some clues. For example, GSK3␤ can phosphorylate the microtubuleassociated protein tau, causing the destabilization of microtubules and collapse of the cytoskeleton. 72, 73 GSK3␤ can also phosphorylate pyruvate dehydrogenase, 74 which may impair the Krebs cycle, and thus affect cellular ATP levels. However, especially intriguing cellular components affected by GSK3␤ are transcription factors. As discussed above, GSK3␤ inhibits the activities of many transcription factors, several of which are known to promote cell survival. Based on this, we hypothesize that GSK3␤-mediated inhibition of cell survival-associated transcription factors contributes to its proapoptotic actions, and conversely, that the neuroprotective action of lithium, discussed further below, stems at least in part from its facilitory effects on transcription factor activation resulting from its inhibition of GSK3␤.
Mood stabilizers inhibit GSK3␤ and are neuroprotective
Although for several years many investigators interested in the mechanisms of action of mood stabilizers thought that effects on intracellular signaling systems were likely to be important, the finding that lithium is a direct inhibitor of GSK3␤ was an unanticipated result. This discovery derived from the insightful observation that lithium's effects on Xenopus development were very similar to those caused by reductions of GSK3␤ activity.
1 Experiments designed to examine this relationship revealed that lithium directly binds and inhibits purified GSK3␤ with an IC 50 of approximately 2 mM, and that lithium inhibits the phosphorylation of substrates of GSK3␤, such as the microtubule associated protein tau. 1 The inhibitory effect of lithium on GSK3␤ was independently reported by Stambolic et al, 2 who further demonstrated that treatment of intact cells with lithium led to reduced GSK3␤ activity in situ, as assessed by the phosphorylation of tau. Since then, numerous additional studies have found that lithium reduces the phosphorylation of tau by inhibiting GSK3␤. [75] [76] [77] [78] It is notable that the measurement of tau phosphorylation has been, and continues to be, prevalent in studies of the effects of lithium on GSK3␤, since tau has probably been studied more than any other protein in this regard. This stems not from a known role of tau in bipolar disorder, although such a possibility is certainly an important issue that needs to be addressed, but from the extensive knowledge about tau and the tools available to study its phosphorylation state. Tau is present in an abnormally hyperphosphorylated state in the neurofibrillary tangles present in the brains of individuals with Alzheimer's disease. 79 Because the phosphorylation of tau may be an important event in the formation of these tangles, and thus in the pathogenesis of the disease, there have been extensive studies of the kinases that mediate phosphorylation of tau, and phosphorylation-dependent antibodies have been produced that are able to identify the site-specific phosphorylation of tau. Thus, it was already known that tau is a substrate of GSK3␤ when the inhibitory effect of lithium was discovered, and antibodies that specifically recognize the GSK3␤-dependent phosphorylation of tau were available, 79 thereby making tau a convenient protein to assess the in situ effects of lithium on GSK3␤. Remaining to be determined is whether this is only a convenient tool to study in situ GSK3␤-mediated substrate phosphorylation, or if lithium's effects on GSK3␤, which modify tau phosphorylation, and thus cytoskeletal plasticity, contribute to the therapeutic effects of lithium as a mood stabilizer.
The discovery that lithium inhibits GSK3␤ provided an important clue about the actions of lithium that provides the basis for many subsequent and ongoing studies. Besides inhibiting GSK3␤, lithium also inhibits the closely related enzyme GSK3␣. 2 Thus, it is important to acknowledge that many of the effects of lithium that are attributed to its inhibition of GSK3␤, and are discussed in this manner in this article, actually are likely to be due to inhibition of both forms of GSK. The specificity of lithium's inhibitory effect on GSK was further validated by Davies et al 80 who reported in an extensive study of 24 different kinases that no other kinase was inhibited more than GSK3␤ by lithium, although mild inhibition by lithium of casein kinase 2 and mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2) was noted. Interestingly, another effective mood stabilizer, sodium valproate, also inhibits GSK3␤. 81 Although little is known about the mechanism by which lithium inhibits GSK3␤, recent evidence indicates that lithium is a competitive inhibitor of GSK3␤ with respect to magnesium. 80, 82 This finding raises the possibility that the in situ inhibitory effect of lithium may be greater than that noted in the initial studies, since lithium's potency is greater in the presence of lower concentrations of magnesium. 80, 82 Although the effects of lithium have been investigated on a wide variety of substrates of GSK3␤, especially intriguing are its modulatory effects on transcription factors. GSK3␤ is known to regulate the activation states of eight transcription factors, including ␤-catenin, AP-1, HSF-1, CREB, NFB, Myc, NFAT, and C/EPB, as discussed above. This raises the possibility that inhibition of GSK3␤ by lithium likely alters the activities of these transcription factors, and by this mechanism lithium may regulate the expression of a diverse array of genes. This may be important because lithium has been reported to alter the expression of numerous genes, and many investigators suspect that lithium's effects on gene expression form an important component of its therapeutic effect.
As discussed above, ␤-catenin cooperates with the TCF/LEF transcription factor family, and phosphorylation of ␤-catenin by GSK3␤ enhances the degradation of ␤-catenin. Several studies have found that lithium treatment increases ␤-catenin levels, an effect highly likely to be due to inhibition of GSK3␤ by lithium. 2, [83] [84] [85] These studies demonstrate that lithium activates the Wnt signaling pathway, which normally involves inhibition of GSK3, an action that may account for numerous observations of developmental effects of lithium. 1, 83 Increased ␤-catenin levels lead to increased transcriptional activation of ␤-catenin/TCF/LEF-regulated genes, a potentially important consequence of long-term lithium treatment.
Several reports have also appeared demonstrating that lithium modulates the activation state of AP-1, effects that might be linked to the inhibitory influence of GSK3␤ on AP-1. In accordance with this, increased AP-1 activity has been reported after lithium treatment in cultured cells and in rat brain. 83, [86] [87] [88] [89] However, although the reported increased AP-1 activity is consistent with lithium causing a blockade of GSK3␤'s inhibition of AP-1, these studies are complicated by the fact that lithium also has other sites of action that may impact on AP-1 DNA binding activity, 90 and none of these studies have directly demonstrated that inhibition of GSK3␤ accounts for the observed actions of lithium on AP-1.
HSF-1, an important transcription factor involved in the survival-promoting response of cells to stress, is also inhibited by GSK3␤. Only recently have the effects of lithium been examined on the activity of HSF-1. Two reports showed that overexpression of GSK3␤ inhibited stress-induced activation of HSF-1, and that lithium reversed the inhibitory effect of GSK3␤. 34, 35 Thus, lithium facilitates HSF-1 activation, and this has definitively been shown to involve inhibition of GSK3␤ by lithium. Since HSF-1 activates the expression of heat shock proteins, which help cells survive many stressful conditions, facilitation by lithium of HSF-1 activity may contribute to lithium's neuroprotective properties. 34 Because modulation of the cyclic AMP second messenger system had been implicated in the mechanism of action of lithium, the initial studies of lithium's effects on CREB activity were designed from this perspective. Ozaki and Chuang 87 found that lithium treatment significantly increased CREB DNA binding activity in cultured cerebellar granule cells and in several regions of rat brain. In contrast, lithium treatment did not increase, but instead decreased, CREB activation in SH-SY5Y cells. 91 In the latter study, cells grown in medium with serum were studied, a condition that maintains GSK3␤ in its inactive state, and thus potential modulatory influences of GSK3␤ and its inhibition by lithium were negated. More recent results demonstrate unequivocally that active GSK3␤ inhibits CREB activity and that inhibition of GSK3␤ by lithium facilitates the activation of CREB. 30 As noted above, GSK3␤ has been reported to both activate and inhibit NFB. 64, 65 Similar opposite results were obtained on examination of the effect of lithium. In the model system demonstrating an inhibitory effect of GSK3␤ on Wnt-1-induced NFB in PC12 cells, lithium increased NFB activity. 65 On the other hand, in the model system demonstrating an activating effect of GSK3␤ on tumor necrosis factor-induced NFB, lithium was inhibitory. 64 In another study, lithium was without effect on carbachol-stimulated NFB DNA binding activity in SH-SY5Y cells. 86 It appears likely from these three disparate results that the influence of lithium on NFB activation is dependent on the signaling systems involved and cell types studied.
The effects of lithium on several other transcription factors regulated by GSK3␤ have yet to be examined. Myc is phosphorylated by GSK3␤, but the functional outcome remains to be clearly established, and modulation by lithium has not been investigated. GSK3␤ phosphorylates and inactivates NFATc. Thus, lithium's inhibition of GSK3␤ can be predicted to increase the activity of NFATc, but this interaction remains to be studied. C/EBP differs from most other transcription factors regulated by GSK3␤ because GSK3␤ contributes to the activation, rather than inhibition, of C/EBP. The influence of lithium on C/EBP was studied in adipocytes, and C/EBP activity was reduced by lithium treatment, apparently due to its inhibition of GSK3␤. 62 Clearly, further studies of the effects of lithium on the activities of Myc, NFAT and C/EBP are likely to reveal further regulatory effects of this mood stabilizer.
Overall, it is evident that because GSK3␤ contributes to the regulation of several transcription factors, there is a great potential for lithium to regulate gene expression through its inhibition of GSK3␤. However, as of now, only a few of these transcription factors have been studied in detail in this regard. Of the GSK3␤-regulated transcription factors, the evidence is strongest for ␤-catenin, HSF-1 and CREB that lithium's inhibition of GSK3␤ contributes to facilitated activation of these transcription factors, whereas lithium likely inhibits C/EBP. Correlative evidence also links lithium's inhibition of GSK3␤ to its influence on the activity of AP-1. The effects of lithium on NFB likely vary with cell type and signaling systems, while potential effects of lithium on Myc and NFAT remain to be investigated. Clearly, these GSK3␤-regulated transcription factors represent potential targets for other mood stabilizers, which may regulate each transcription factor via other mechanisms, allowing an overlap of outcomes achieved by distinct mechanisms of action ( Figure 2 ).
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GSK3␤-associated signaling systems and cell fate: a target for mood-stabilizing drugs
In addition to inhibiting GSK3␤, and thereby modulating transcription factor activities, lithium is also a neuroprotectant. We hypothesize that neuroprotection by lithium is, at least in part, due to inhibition of GSK3␤, which may stem from the regulatory effects of GSK3␤ on transcription factors. There is now an extensive number of reports showing that lithium is a neuroprotectant, enhancing the survival of cells exposed to potentially lethal conditions. These reports are summarized in Table 1 . As indicated in Table 1 , several investigators reported neuroprotective properties of lithium between 1993 and 1997, but between 1998 and the present there has been a tremendous increase in the number of reports demonstrating neuroprotection by lithium. Especially remarkable is the in vivo neuroprotection provided by lithium for ischemia-induced neuronal loss.
14,108 Also notable is the wide variety of toxic insults towards which lithium affords protection. This diversity suggests that lithium affects a fundamental cell survival mechanism that is capable of influencing cellular responses to diverse stimuli. Based on this, GSK3␤ appears to be a likely target for lithium's neuroprotective effects, since GSK3␤ is inhibitory for the activation of several transcription factors that, when activated, are well-known to contribute to cell survival. Thus, under different conditions, ␤-catenin, AP-1, HSF-1, CREB, NFB and Myc can each promote cell survival. Therefore, lithium's enhancement of the activities of these transcription factors through attenuation of the inhibitory influence of GSK3␤ provides the diversity necessary for lithium to promote cell survival against a broad array of toxic conditions. Although the diversity of lithium's neuroprotectant effects is well documented, little information is available in which the protective mechanism of action of lithium was directly assessed. In order to address this problem, we established apoptotic model systems in which a particular component of apoptosis was definitively attributable to GSK3␤. This was attained using human neuroblastoma SH-SY5Y cells that overexpress GSK3␤ by three-to four-fold above the endogenous level. In these cells, apoptosis induced by staurosporine or heat shock was enhanced by overexpressed GSK3␤, and pretreatment with lithium blocked the GSK3␤-mediated enhancement of apoptosis. 68 Thus, a specific component of apoptosis was attributable to GSK3␤, and this component was blocked by lithium. These experiments provide a proof-of-principle, that lithium's inhibition of GSK3␤ can provide neuroprotection. Taken in conjunction with the increasing evidence that endogenous GSK3␤ contributes to, and is necessary for, apoptosis signaling cascades induced by a broad spectrum of proapoptotic agents, we propose that a key neuroprotective mechanism of action of lithium derives from its inhibition of GSK3␤.
The neuroprotection provided by lithium's inhibition of GSK3␤ raises the question of whether this is an action shared by other mood stabilizers. Evidence Figure 2 Potential targets of mood stabilizers that would modulate the effects of GSK3␤. The activity of GSK3␤ may be modulated by mood stabilizers by a direct action on GSK3␤, or by actions on signaling pathways upstream of GSK3␤ that lead to the phosphorylation or dephosphorylation of GSK3␤, thereby modulating the activity of GSK3␤ indirectly. Alternatively, mood stabilizers may act on downstream targets of GSK3␤, either directly or indirectly by affecting signaling pathways leading to the target, to modify the functional effect of GSK3␤ without actually changing the activity of GSK3␤. Thus, mood stabilizers may have different mechanisms of action but still share the same functional effect on certain targets of GSK3␤. ing for protection by lamotrigine has not been investigated. It should be noted that to provide protection from apoptosis signaling cascades involving GSK3␤, a protective agent need not directly inhibit GSK3␤, since GSK3␤ also can be inhibited by phosphorylation of ser-9, a modification mediated by several kinases, as discussed above and depicted in Figure 1 . Additionally, protective agents instead may act downstream of GSK3␤, eg, by increasing the activity of a transcription factor that is inhibited by GSK3␤, thereby negating the influence of GSK3␤ (Figure 2 ).
Conclusion
Several conclusions can be drawn from the recent studies of the effects of lithium and other mood stabilizers on GSK3␤ and on signaling cascades associated with GSK3␤. It is now evident that several critical signaling cascades merge at GSK3␤, and that GSK3␤, in turn, exerts influence on multiple transcription factors as well as other proteins, thus modulating the outcomes of many signaling cascades that regulate the activities of these transcription factors (as depicted in a simplified manner in Figure 1 ). Thus, mood stabilizers may have modulatory effects on signaling cascades that lead to the regulation of GSK3␤, they may directly regulate GSK3␤ or they may regulate targets of GSK3␤ to counteract the actions of GSK3␤ (Figure 2 ). Therefore, different target sites may lead to common outcomes. The recent revelations of the widespread modulatory actions of GSK3␤ in cellular signaling cascades and the influences of lithium on GSK3␤-mediated regulatory interactions provide insight into lithium's mechanism of action and provide investigational targets for studying the actions of newly developed mood stabilizers.
